Ticagrelor is a clinically approved reversible platelet aggregation inhibitor that exhibits anticoagulant and antithrombotic activities. Ticagrelor is primarily used to increase coronary blood flow velocity and to prevent stroke, heart attack, and myocardial infarction. This compound has a rapid onset and offset of action and has been shown to act as a nucleoside analog with an overall similarity to adenosine; it is an allosteric antagonist for the P2Y12 ADP receptor, inhibiting downstream fibrinogen cross-linking between platelets.

**References**


---

**Product Information**

<table>
<thead>
<tr>
<th>Product ID</th>
<th>Size</th>
<th>List Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>T3200</td>
<td>5 mg</td>
<td>$67.40</td>
</tr>
<tr>
<td>T3200</td>
<td>25 mg</td>
<td>$247.30</td>
</tr>
<tr>
<td>T3200</td>
<td>100 mg</td>
<td>$636.80</td>
</tr>
</tbody>
</table>

**Formula**

C_{23}H_{28}F_{2}N_{6}O_{4}S

**CAS No.**

274693-27-5

**Description**

Ticagrelor is a clinically approved reversible platelet aggregation inhibitor that exhibits anticoagulant and antithrombotic activities. Ticagrelor is primarily used to increase coronary blood flow velocity and to prevent stroke, heart attack, and myocardial infarction. This compound has a rapid onset and offset of action and has been shown to act as a nucleoside analog with an overall similarity to adenosine; it is an allosteric antagonist for the P2Y12 ADP receptor, inhibiting downstream fibrinogen cross-linking between platelets.

**Synonym**

AZD-6140

---

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.